The Chronicle of Neurology & Psychiatry Dec. 2016 by The Chronicle of Neurology & Psychiatry

ADVERTORIAL

I AM PROOF THAT STROKE CAN HAPPEN AT ANY AGE

SHANNON RICHARDS THOUGHT SHE WAS TOO YOUNG TO HAVE A STROKE

“Stroke can happen at any age, but you can always move forward from it.” Pre-interview jitters seemed to be getting the best of Shannon Richards. Hours away from a job interview, the 29-year-old had spent the morning in her bedroom, trying to shake off an upset stomach and throbbing headache. “I felt really dizzy. It was almost like somebody pushed me,” she recalls. Unable to keep her balance, Shannon called for her mother, Susan, before crumpling to the floor. Susan came running and found her daughter on the floor, slurring her words. The left side of Shannon’s face was drooping. “I remember my mom saying, ‘I think you’re having a stroke.’”

Susan called 9-1-1. Within minutes, Shannon was in the back of an ambulance, racing to the nearest hospital in Sault Ste. Marie, Ont. Doctors quickly determined that Shannon was having an ischemic stroke, an interruption in the brain’s blood flow caused by a blood clot. Because of her mom’s fast response, Shannon got to hospital in time to receive tPA, a clot-busting drug that helps restore blood flow to the brain. Researchers funded by the Heart and Stroke Foundation pioneered the use of tPA for stroke patients. To be effective, it must be given within 4½ hours of the onset of symptoms. Seven years later, Shannon hopes her story will help others. “Stroke can happen at any age, but you can always move forward from it. I’m proof of that.”

STROKE SIGNS Stroke is a medical emergency. If you or someone you know has any of these signs, call 9-1-1 immediately.*

VISION PROBLEMS

WEAKNESS

HEADACHE

TROUBLE SPEAKING

DIZZINESS

*Or call your local emergency number.

Help create more survivors like Shannon. Learn more at heartandstroke.ca/stroke

Walking impairment in multiple sclerosis

I can hold it for 1 minute. I need 1.2 minutes to get there. If only I could walk faster.

A significantly greater proportion of patients taking FAMPYRA 10 mg twice daily were responders, compared to patients taking placebo (34.8% vs. 8.3% in MS-F203 and 42.9% vs. 9.3% in MS-F204, respectively), as measured by the Timed 25-foot Walk Test (primary endpoint).*† FAMPYRA™ (fampridine) sustained release tablets are indicated for the symptomatic improvement of walking in adult patients with multiple sclerosis (MS) with walking disability (EDSS 3.5–7).

Refer to the page in the bottom-right icon for additional safety information and for a web link to the product monograph discussing: •

Contraindications in patients with known hypersensitivity to the drug fampridine or to any ingredient in the formulation or component of the container, concurrently taking compounded 4-aminopyridine or other forms of fampridine, with mild, moderate or severe renal impairment, with prior history or current presentation of seizure, taking medicinal products that are inhibitors of the renal Organic Cation Transporter 2 (OCT2), such as cimetidine and quinidine

•

Relevant warnings and precautions regarding timing of doses, determination and monitoring of renal function, seizure risk, carcinogenesis and mutagenesis, caution in cardiovascular symptoms and disorders, low white blood cell counts and infections, neurological, dizziness and balance disorders, dizziness and fatigue, exacerbation of trigeminal neuralgia, occupational hazards, urinary tract infections, use during pregnancy and not recommended during breastfeeding

•

Conditions of clinical use, adverse events, drug interactions, missed dose, and dosing instructions

In addition, the page contains the reference list and study parameters relating to this advertisement. * A responder was defined as a patient whose walking speed on at least 3 of the 4 treatment visits was faster than the fastest speed during any of the 5 ‘no treatment’ visits.

fampridine Sustained release tablets

FAMPYRA™ is manufactured under license from Alkermes Pharma Ireland Ltd, (APIL), utilizing APIL’s MatriX Drug Absorption System (MXDASTM) technology. FAMPYRA™ is a trademark of Acorda Therapeutics, Inc.

See additional safety information on 11

 

                                     

                     

            

 

      

       

                 

       

NEW INTERFERON OPTION. PLEGRIDY™ (peginterferon beta-1a) is the first and only interferon for relapsingremitting MS with an every-2-week dosing schedule1*

PLEGRIDY achieved significant results in the following clinical and MRI endpoints at 1 year vs. placebo2† 36% reduction in annualized relapse rate with PLEGRIDY vs. placebo

PLEGRIDY, 0.256; placebo, 0.397; p=0.0007

38% risk reduction in proportion of patients with disability progression (12 weeks, secondary endpoint) with PLEGRIDY vs. placebo

PLEGRIDY, 0.068; placebo, 0.105; p=0.0383

67% reduction in new or newly enlarging T2 hyperintense lesions (secondary endpoint) with PLEGRIDY vs. placebo

PLEGRIDY, 3.6; placebo, 10.9; p<0.0001

Demonstrated safety and tolerability profile2 The most common side effects with PLEGRIDY were injection site erythema (62%), influenza like illness (47%), pyrexia (45%), headache (44%), myalgia (19%), chills (17%), injection site pain (15%), asthenia (13%), injection site pruritus (13%), and arthralgia (11%). Subcutaneous injection with a pre-filled pen every two weeks2

PLEGRIDY is indicated for the treatment of relapsing remitting multiple sclerosis (RRMS) for adult patients • to reduce the frequency of clinical exacerbations • to slow the progression of disability. Refer to the page in the bottom-right icon for additional safety information and for a web link to the product monograph discussing: • Contraindications in patients with a history of hypersensitivity to natural or recombinant interferon beta or peginterferon, with a history of hypersensitivity to, any other component of the formulation or the container, pregnant patients, and patients with current severe depression and/or suicidal ideation • Relevant warnings and precautions regarding supervision of the first injection, important information for patients,

elevations in hepatic enzymes and hepatic injury, depression, suicide, and other severe psychiatric symptoms, hypersensitivity reactions, injection site reactions, decreases in peripheral blood counts and cytopenias, laboratory abnormalities associated with interferons and recommendations for blood monitoring, seizure, cardiovascular disease, development of antibodies to PLEGRIDY, hyperthyroidism, metabolism and nutrition disorders, and cautions in patients with hepatic impairment or taking drugs associated with hepatic injury • Conditions of clinical use, adverse events, drug interactions, and dosing In addition, the page contains the reference list and study parameters relating to this advertisement.

MS = multiple sclerosis

See additional safety information on 17

Thank you , Gracias, Merci, Grazie, ありがとう,

do jeh, Danke sehr, Khop Khun, Mak Kha, Spasiba, 감사합니다, Takk, Mahalo, Toda, Efharisto WE’VE PROUDLY TREATED OVER 152,500 PATIENTS IN 77 DIFFERENT COUNTRIES. 1

10 YEARS

TYSABRI is indicated as monotherapy (i.e. single disease-modifying agent) for the treatment of patients with the relapsing-remitting form of multiple sclerosis (MS) to reduce the frequency of clinical exacerbations, to decrease the number and volume of active brain lesions identified on magnetic resonance imaging (MRI) scans and to delay the progression of physical disability. TYSABRI is generally recommended in MS patients who have had an inadequate response to, or are unable to tolerate, other therapies for multiple sclerosis. Consult the product monograph at http://webprod5.hc-sc.gc.ca/dpd-bdpp/index-eng.jsp for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The product monograph is also available by contacting Biogen Canada Inc. at 1-866-477-3462. Reference: 1. Data on file. Medical Affairs letter; August 30, 2016. Biogen Canada Inc.